STOCKS TELEGRAPH

Tag: Entera Bio

  • 3 Stocks Gaining Attention Across Markets: Armata Pharmaceuticals (ARMP), Entera Bio (ENTX), Cardiol Therapeutics (CRDL)

    3 Stocks Gaining Attention Across Markets: Armata Pharmaceuticals (ARMP), Entera Bio (ENTX), Cardiol Therapeutics (CRDL)

    Operating in today’s biotech sector requires more than groundbreaking science—it demands careful execution and strategic discipline. With financial conditions becoming more challenging, companies are facing heightened scrutiny over how they allocate resources and move their pipelines forward. This evolving landscape has placed greater emphasis on predictable development timelines, well-organized clinical studies, and active dialogue with regulatory bodies.

    Armata Pharmaceuticals Inc (ARMP)

    Armata Pharmaceuticals Inc (NYSEAMERICAN: ARMP) opened the trading on April 29, 2026, with a bit cautious approach as it glided -2.15% to $9.55. During the day, the stock rose to $10.85 and sank to $9.17. Taking a more long-term approach, ARMP posted a 52-week range of $1.17-$16.34.

    The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded 28.83%. Meanwhile, its Annual Earnings per share during the time were -28.83%.  Nevertheless, the stock’s Earnings Per Share (EPS) this year is 76.04%. This publicly-traded company’s shares outstanding now amount to $36.43 million, simultaneously with a float of $11.27 million. The organization now has a market capitalization of $349.84 million.

    Entera Bio Ltd (ENTX)

    Entera Bio Ltd (NASDAQ: ENTX) started the day on April 29, 2026, with a price decrease of -0.88% at $1.12. During the day, the stock rose to $1.20 and sank to $1.11. Taking a more long-term approach, ENTX posted a 52-week range of $0.91-$3.22.

    It was noted that the giant of the Healthcare sector posted annual sales growth of 16.47% over the last 5 years. Meanwhile, its Annual Earnings per share during the time was 16.47%.  Nevertheless, the stock’s Earnings Per Share (EPS) this year is -68.00%. This publicly-traded company’s shares outstanding now amount to $46.18 million, simultaneously with a float of $37.61 million. The organization now has a market capitalization of $52.22 million.

    Cardiol Therapeutics Inc. (CRDL)

    Cardiol Therapeutics Inc. (NASDAQ: CRDL) is advancing a broader pipeline strategy aimed at capturing value in large-scale cardiovascular markets, particularly in heart failure, where unmet need remains substantial. By extending beyond its lead asset, the company is positioning itself for long-term growth through diversified therapeutic applications.

    Market Momentum

    As of April 29, 2026, CRDL closed at $1.31, down 4.38%, with trading volume (552,696 shares) below its average of 680,359 shares—indicating measured selling pressure. With a market cap of $146.301M and a beta of 0.43, the stock continues to exhibit relatively low volatility. It trades within its 52-week range ($0.8800–$1.71), while a 1-year target estimate of $7.47 suggests meaningful upside potential as development programs advance.

    Pipeline Expansion: CRD-38

    Cardiol is developing CRD-38, a next-generation, subcutaneous therapy designed for improved convenience and broader clinical use, particularly in heart failure. The therapy targets both inflammation and fibrosis—key drivers of disease progression that are not fully addressed by current standards of care.

    Market Opportunity

    Heart failure represents a multi-billion-dollar global market with millions of patients and limited treatment options specifically targeting inflammatory pathways. By advancing CRD-38, Cardiol is positioning itself to enter a large and underserved segment, significantly expanding its long-term commercial opportunity.

    Outlook

    As CRD-38 progresses toward clinical development, it could emerge as a major value driver. Success in this program would strengthen Cardiol’s growth profile and support its transition into a more diversified cardiovascular biotech company.

  • Entera Bio, Ltd. (ENTX) Stock Skyrockets After Being Granted European Patent

    Entera Bio, Ltd. (ENTX) Stock Skyrockets After Being Granted European Patent

    Entera Bio, Ltd. (ENTX) stock prices surged by a massive 24.76% as of the market closing on June 17th, 2021, bringing the price per share up to USD$5.19 at the end of the trading day. Subsequent pre-market fluctuations have seen the stock inch up by another 0.19%, bringing it up to USD$5.20.

    Patent Granted

    The company announced on June 17th, 2021 that it had been granted a patent titled “Methods and Compositions for Oral Administration of Protein’s” by the European Patent office. The patent secures a marketspace for the companies PTH formulations that are currently in advanced clinical stages for osteoporosis and hypoparathyroidism.

    Safeguarding Intellectual Property

    The critical patent covers leading PTH treatment products that are based on the company’s platform technology. The newly granted patent, in conjunction, with a myriad of other patents that cover oral formulations and target indications, facilitate the provision of robust protection for ENTX’s intellectual property. Besides the EU patent, the company has been granted strategic patents from countries including, but not limited to, USA, China, Japan, Australia, and New Zealand.

    Scope of Patent

    Especially promising was the recent news of the successful completion of the none-month time window during which the patent could have been challenged. The company is keen to consolidate its position as a market leader in the oral delivery of proteins in the wake of the upcoming six-month BMD result reports from the Phase 2 study. Phase 2 is scheduled for the second quarter of fiscal 2021. The company also has plans to potentially initiate a pivotal Phase 3 study next year, designed to evaluate the company’s oral PTH treatment of osteoporosis.

    About ENTX

    ENTX is an established leader in the development of large molecule therapeutics that are delivered orally, with the company targeting areas with significant unaddressed medical needs. Penetration is highest in markets where the use of injectable therapies is limited for various reasons, including cost, convenience, or compliance issues for patients. The company is spearheading efforts to address standard technical challenges of poor absorption high variability, and the inability to effectively ensure delivery of large molecules to the intended locations in the body.

    Future Outlook for ENTX

    Armed with this ground-breaking development, ENTX is poised to continue its trajectory of success by preparing itself to successfully execute the market proliferation of its patented treatment. Current and potential investors are hopeful that management will continue to leverage the resources at their disposal to facilitate significant and sustained increases in shareholder value.

  • Entera Bio Ltd (ENTX) stock plunged in the pre-market trading session; Here’s what’s happening

    Entera Bio Ltd (ENTX) stock showed a positive movement by 8.7% in the recent trading session where the stock’s price was $4.00. It previously closed at $3.68. However, in the pre-market trading session, the stock plunged by 9% at the time of writing.

    Recent news related to Entera Bio comes in the form of another Bio-pharmaceutical company-Abeona Therapeutics recently announcing two new independent board members to its board of directors. One of the newly appointed members includes a member of the Board of Directors in Entera Bio (ENTX).

    Entera Ltd. (ENTX)’s core focus

    Entera Bio Ltd. is a biotech company that specifically focuses on delivering large molecule therapeutics through oral administration. This large molecule therapeutics is used in the base of clinically-unmet medical needs. Administration of injectable therapies is expensive as compared to oral therapies which is why the focus on the latter is more efficient and easily supplied. However, oral administration may come upon hurdles of high-exposure to open air contamination, poor absorption and lack of synthetic absorber for large molecule dosage. ENTX has set its sight to deal with these technicalities to bridge the gap.

    BOD member of ENTX has joined the Board committee of Abeona Therapeutics Ltd.

    The member of the Board of Directors in Entera (ENTX) who is now serving in the newly appointed chair of BOD in Abeona, is known by the name of Faith L. Charles. Ms. Charles has 30 years of experience in legal profession and has specifically served sciences based companies. She has worked with several such companies. In Entera her title is that of the member Audit Committee and Chair of the Compensation Committee. Furthermore her business conduct is always associated with that of a valuable insight provider of capital markets and expert in corporate governance.

    How is the overall outlook for ENTX stock?

    On 18th March, ENTX released the financial and operating results for the fourth quarter and Full Year ended 31 December, 2020.

    The highlights for its operational activities for the Full-Year 2020 are as such:

    • Entera (ENTX) had the approval of EB613 IND from the FDA, for the Treatment of Osteoporosis. This allows progress for initial U.S clinical trials.
    • Successfully achieved primary endpoint for phase 2 clinical trial of EB613
    • Data regarding and including Bone Mineral Density is expected in Q2:21
    • Amgen Collaboration is showing progress by further evaluation of molecules like GLP-2

    The financial results for its FY 2020 showed overall improvement with the only relative underperformances:

    • Revenues for 31, Dec FY 2020 were $365,000 compared to $236,000 for 31, Dec FY 2019
    • Operating expenses were $11.3 million for 31, Dec FY 2020 as compared to $11.5 million for 31, Dec FY 2019
    • R&D expenses were $6.4 million for FY 2020 compared to $7.2 million for FY 2019
    • General administrative expenses were $4.9 million for 31, Dec FY 2020 compared to $4.3 million in 31, Dec FY 2019
    • Cash and cash equivalents were equal to $8.6 million at the end of FY 2020 compared to $15.2 million in 31, Dec FY 2019

    Entera (ENTX) consists of a lot of clinical trials in the pipelines that are showing progress. The continued advances in these trials will give the operational outcomes a boost for ENTX stock in the year 2021. These operational outcomes can then be further reflected on its financial activity health.

  • Don’t Miss these 15 Biotechnology Value Stocks

    Biotech and Major Pharmaceuticals are back in the news with the Covid-19 Pandemic. Life science investors basically endorse developments that might decide the human race’s future, but what would invest in ‘cures’ mean from a cash flow point of view?
    On Thursday, a panel of independent health professionals voted 17-4 in support of the Food and Drug Administration(FDA), providing emergency permission to the applicant for the COVID-19 vaccine from BioNTech and Pfizer Inc.
    In other news Gilead Sciences Inc (GILD) revealed that it would buy MYR GmbH in cash for roughly EUR 1.15 billion ($1.39 billion), granting it access to the German biotech company’s therapy for extreme viral hepatitis.
    In yesterday’s trading session, the following stocks were the major key players.

    Immutep Limited (NASDAQ:IMMP) shares were trading up 163.43% at $5.69 at the time of writing on Thursday after declaring that its Chinese partner, EOC Pharma will commence a new Phase II clinical trial in up to 152 metastatic breast cancer patients in China.

    Immutep Limited (NASDAQ:IMMP) share price went from a low point around $0.53 to briefly over $3.10 in past 52 weeks, though shares have since pulled back to $5.69. IMMP market cap has remained high, hitting $280.46M at the time of writing.

    If we look at the recent analyst rating IMMP, B. Riley FBR initiated coverage on IMMP shares with a Buy rating.

    TG Therapeutics Inc. (TGTX) stock soar by 40.85% to $41.72 after reportingpositive topline results from the ULTIMATE I & II Phase 3 studies evaluating Ublituximab Monotherapy for the treatment of patients with multiple sclerosis. The most recent rating by JP Morgan, on September 01, 2020, is at an Overweight.

    Heat Biologics Inc. (HTBX) last closed at $0.93, in a 52-week range of $0.19 to $4.30.

    Sangamo Therapeutics Inc. (NASDAQ:SGMO) Shares headed rising, higher as much as 52.98%. Pfizer Inc. (PFE) and Sangamo Therapeutics, Inc. (SGMO), on December 7, 2020 declared updated follow-up data from the Phase 1/2 Alta study of giroctocogene fitelparvovec (SB-525 or PF-07055480), an investigational gene therapy for patients with severe hemophilia A. The most recent rating by BofA Securities, on September 08, 2020, is at a Buy.

    Entera Bio Ltd. (NASDAQ:ENTX) rose 8.18% after gaining more than $0.09 on Thursday following the firm revealed FDA approval of IND application for EB613 – an Oral Human Parathyroid Hormone (1-34) for the treatment of Osteoporosis.

    Aytu BioScience Inc. (AYTU) last closed at $8.13, in a 52-week range of $3.35 to $29.90 after announcing definitive merger agreement with Neos Therapeutics, creating a combined $100M revenuespecialty pharmaceutical company.

    Amarin Corporation plc (AMRN) stock soar by 8.04% to $4.97. The most recent rating by JP Morgan, on September 29, 2020, is at a Neutral.

    Editas Medicine Inc. (NASDAQ:EDIT) Shares headed rising, higher as much as 32.15% following an announcement from the company that it submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1/2 clinical trial of EDIT-301. The most recent rating by Wells Fargo, on December 10, 2020, is at an Overweight.

    Hepion Pharmaceuticals Inc. (NASDAQ:HEPA) rose 9.04% after gaining more than $0.15 on Thursday.

    Akebia Therapeutics Inc. (AKBA) last closed at $2.95, in a 52-week range of $2.09 to $13.71. The firm recently revealed the latest scheduled program of AkebiaShares, a peer-to-peer educational series for the kidney community.

    BioCryst Pharmaceuticals Inc. (BCRX) stock soar by 5.37% to $7.65. The company recently announced transactions with Royalty Pharma (RPRX) and Athyrium Capital Management, LP, totaling $325 million in funding for BioCryst, with $250 million available at closing, to support the launch of ORLADEYO™ (berotralstat) in hereditary angioedema (HAE) and the development of its oral Factor D inhibitor, BCX9930. The most recent rating by JP Morgan, on September 29, 2020, is at an Overweight.

    Acasti Pharma Inc. (NASDAQ:ACST) Shares headed rising, higher as much as 1.70%. The company on November 16, 2020 released its operating and financial results for the second quarter of fiscal 2021 ended September 30, 2020. The most recent rating by Oppenheimer, on September 01, 2020, is at a Perform.

    Ocugen Inc. (NASDAQ:OCGN) fall -1.79% after losing more than -$0.01 on Thursday after reporting that it will postpone its 2020 Annual Meeting of Stockholders to December 23, 2020.

    Inovio Pharmaceuticals Inc. (INO) last closed at $11.36, in a 52-week range of $2.42 to $33.79. The firm recently revealedthe successful dosing of its first subject in its Phase 2 clinical trial for COVID-19 DNA vaccine candidate, INO-4800, in China. Analysts have a consensus price target of $13.71.

    Cellectar Biosciences Inc. (CLRB) stock soar by 3.47% to $2.09. The most recent rating by Oppenheimer, on July 01, 2020, is at an Outperform.